About eftrenonacog alfa
Recombinant factor IX clotting factor
Used for
- Prevention and treatment of bleeding in haemophilia B
- Control of bleeding during surgery in haemophilia B
Usual adult dose
Individualised by weight, bleeding severity, and treatment goal; commonly 50 IU/kg weekly for prevention.
Usual dose in children
Individualised by weight and treatment goal; commonly 50 IU/kg weekly for prevention.
Common side effects
- Headache
- Injection-site reactions
- Allergic reactions
- Development of factor IX inhibitors
Important warnings
- Seek urgent care for severe allergic symptoms, including breathing difficulty or facial swelling.
- Factor IX inhibitors can reduce treatment effectiveness and require specialist assessment.
- Risk of blood clots, especially with high doses or existing clotting risks.
- Use only the supplied diluent and administer by intravenous injection.
Pregnancy
Limited pregnancy data; use only when clearly needed, with specialist oversight.
Breastfeeding
Unknown whether it passes into breast milk; use requires assessment of benefits and risks.
Interactions
- No major drug interactions are established; tell clinicians about all medicines and clotting treatments.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.